H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on vTv Therapeutics today and set a price target of $36.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Emily Bodnar has given her Buy rating due to a combination of factors surrounding vTv Therapeutics. The company has made significant progress in its clinical trials, particularly with the re-initiation of the Phase 3 CATT1 trial for cadisegliatin, a novel treatment for Type 1 diabetes. The swift activation of clinical sites and the strategic reduction in trial duration are seen as positive steps that could expedite the path to larger pivotal studies and ultimately support a New Drug Application submission.
Additionally, the safety profile of cadisegliatin has been well-received, with the FDA lifting a previous clinical hold and granting Breakthrough Therapy Designation, which underscores its potential to significantly improve existing treatments. The promising results from earlier studies, such as the Phase 2 SimpliciT1 trial, further bolster confidence in the drug’s efficacy and safety. These developments, along with the strengthening of the company’s intellectual property portfolio, contribute to the optimistic outlook and Buy rating for vTv Therapeutics’ stock.